Public company intelligence preview
ERASCA INC
28 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $3.0M average total compensation across covered insiders.
Governance movement
Public aggregate: 0 governance events in the last year.
Institutional ownership
Public aggregate: 154 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Erasca Inc. is a Healthcare company in the Biotechnology industry focused on clinical-stage precision oncology. Its core mission is to develop therapies for cancers driven by the RAS/MAPK pathway, with lead programs including ERAS-0015, ERAS-4001, and the earlier-stage ERAS-12. The company has no commercial products yet and remains dependent on successful clinical development, regulatory approval, and external manufacturing and distribution partners. Recent filings show a strategic shift away from legacy programs and toward its differentiated RAS franchise, with management prioritizing pipeline execution and capital efficiency.
Executive Compensation Practices
For a development-stage biotech like Erasca, executive compensation is likely driven more by clinical milestones, regulatory progress, cash runway management, and strategic portfolio decisions than by revenue growth or profitability. In this case, compensation metrics are likely tied to advancement of ERAS-0015 and ERAS-4001, IND clearance, Phase 1 readouts, and the successful execution of licensing or partnership strategy, since the company has no product sales. Because the company is still reporting significant net losses and ongoing R&D spending, equity-based compensation is likely to be an important part of total pay, helping align management with long-term value creation. Stock-based awards may also be structured around retention and milestone achievement, especially given the company’s heavy reliance on scientific execution and capital markets access.
Insider Trading Considerations
Insider trading activity in a Biotechnology company like Erasca often reflects the binary nature of clinical data and regulatory catalysts. Trading may cluster around major events such as Phase 1 data readouts, IND clearances, trial reprioritizations, or partnership announcements, all of which can materially move the stock. Because Erasca depends on external financing and reports a long cash runway into 2028, insider transactions may also reflect management’s view on dilution risk, capital needs, or confidence in near-term pipeline progress. Researchers should pay close attention to transactions around clinical updates for ERAS-0015 and ERAS-4001, as these programs are the main value drivers and likely the primary focus of insider sentiment.
Unlock the full ERAS insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.